Keystone Symposia

Herrenhausen Palace Floorplan

Registered Attendees


Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:

  • Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting (You can edit your own abstract from My Account page as well)

    NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.

  • Full participant list, including joint meeting participants
  • Printable Invoices and Invitation Letters
  • Scholarship Information
  • Lodging Information

Login to My Account page

This meeting took place in 2020



For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.

MEETING CANCELLED: PI3-Kinase and PTEN at the Interface of Cell Growth, Vesicular Trafficking and Disease (E1)


Organizer(s) Bart Vanhaesebroeck, Volker Haucke and Lori Friedman
May 3—7, 2020
Herrenhausen Palace • Hannover, Germany
Discounted Abstract Deadline: Jan 7, 2020
Abstract Deadline: Feb 20, 2020
Scholarship Deadline: Jan 7, 2020
Discounted Registration Deadline: Mar 3, 2020

Organized in collaboration with Volkswagen Foundation

Summary of Meeting:
The Phosphoinositide 3-Kinase (PI3K) signaling pathway is a main regulator in cell growth, metabolism, and survival and Phosphatase and TENsin homolog (PTEN) is a tumor suppressor gene. This conference integrates three decades of research and development in the PI3K/PTEN field and its progression towards the understanding and treatment of human disease. The discovery of rare human disorders arising from deregulation of the PI3K/PTEN pathway is providing important insights into the organismal biology of this pathway, as well as reviving interest in the repurposing of PI3K pathway inhibitors that were originally under development as anti-cancer agents. In addition, improved strategies to effectively use PI3K inhibitors in cancer are progressing through the clinic, with exciting new opportunities to use PI3K inhibitors in cancer immunotherapy treatment. This conference will cover the mechanism of action of the phosphoinositide lipids, their turnover and their downstream effectors, especially in relation to the class II and III PI3K isoforms, whose cellular and organismal functions are gradually being uncovered. Furthermore, the program will emphasize the emerging evidence for a critical role of the PI3K/PTEN pathway in neuronal biology, immunology and autophagy. This conference brings together basic scientists, drug developers and clinicians under one venue to discuss new paradigms in the field. Thus, this conference will catalyze information exchange and spark collaborations that will foster further scientific progress toward the improvement of human health.

View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference

Conference Program    Print  |   View meeting in 12 hr (am/pm) time


Program is being updated. Please check back soon for program details.